• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Immunol . Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules

tetano

Editor, Senior Moderator
Nat Immunol


. 2022 Jan 31.
doi: 10.1038/s41590-021-01114-w. Online ahead of print.
Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules


Matteo Stravalaci[SUP] #[/SUP][SUP] 1 2 [/SUP], Isabel Pagani[SUP] #[/SUP][SUP] 3 [/SUP], Elvezia Maria Paraboschi[SUP] 1 2 [/SUP], Mattia Pedotti[SUP] 4 [/SUP], Andrea Doni[SUP] 1 [/SUP], Francesco Scavello[SUP] 1 [/SUP], Sarah N Mapelli[SUP] 1 [/SUP], Marina Sironi[SUP] 1 [/SUP], Chiara Perucchini[SUP] 1 [/SUP], Luca Varani[SUP] 4 [/SUP], Milos Matkovic[SUP] 4 [/SUP], Andrea Cavalli[SUP] 4 5 [/SUP], Daniela Cesana[SUP] 6 [/SUP], Pierangela Gallina[SUP] 6 [/SUP], Nicoletta Pedemonte[SUP] 7 [/SUP], Valeria Capurro[SUP] 7 [/SUP], Nicola Clementi[SUP] 8 [/SUP], Nicasio Mancini[SUP] 8 [/SUP], Pietro Invernizzi[SUP] 9 10 [/SUP], Rafael Bayarri-Olmos[SUP] 11 [/SUP], Peter Garred[SUP] 11 [/SUP], Rino Rappuoli[SUP] 12 13 [/SUP], Stefano Duga[SUP] 1 2 [/SUP], Barbara Bottazzi[SUP] 1 [/SUP], Mariagrazia Uguccioni[SUP] 2 4 [/SUP], Rosanna Asselta[SUP] 1 2 [/SUP], Elisa Vicenzi[SUP] 14 [/SUP], Alberto Mantovani[SUP] 15 16 17 [/SUP], Cecilia Garlanda[SUP] 18 19 [/SUP]



Affiliations

Abstract

The humoral arm of innate immunity includes diverse molecules with antibody-like functions, some of which serve as disease severity biomarkers in coronavirus disease 2019 (COVID-19). The present study was designed to conduct a systematic investigation of the interaction of human humoral fluid-phase pattern recognition molecules (PRMs) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of 12 PRMs tested, the long pentraxin 3 (PTX3) and mannose-binding lectin (MBL) bound the viral nucleocapsid and spike proteins, respectively. MBL bound trimeric spike protein, including that of variants of concern (VoC), in a glycan-dependent manner and inhibited SARS-CoV-2 in three in vitro models. Moreover, after binding to spike protein, MBL activated the lectin pathway of complement activation. Based on retention of glycosylation sites and modeling, MBL was predicted to recognize the Omicron VoC. Genetic polymorphisms at the MBL2 locus were associated with disease severity. These results suggest that selected humoral fluid-phase PRMs can play an important role in resistance to, and pathogenesis of, COVID-19, a finding with translational implications.
 
Back
Top Bottom